Pharm. Sarah Jonathan Yusuf (Mrs)
MD/CEO & Chief Pharmacist, Malbo Pharmacy
Sarah is a Community Pharmacist, an Entrepreneur and the co-founder and MD/CEO of Malbo Pharmacy. A Company borne from her passion to improve the challenges of fake/counterfeit drugs and lack of professional advice on proper use of medication as a result of overwhelmed health facilities and personals in our health care delivery system. These challenges motivated Pharm Sarah to contribute her quota in improving access to quality medication and health care products, as well as provision of a medium for drug information services to patients to achieve maximum therapeutic benefits.
To further extend the outreach of her services, she launched Nigeria's foremost Online Pharmacy Mall & Drugstore through which she provides Online Pharmacy Services and in addition, to increase awareness on health related and medication information to patients/customer, she operates one of the only active Pharmacy Blog in the country where writes writes health promotional articles/leaflets for distribution to thousands of subscribers.
Prompted by her desire to increase the scope of her knowledge on drug mechanisms and action couple with the ambition to positively contribute to the field of research, she obtained a Master’s of Science Degree in Pharmacology and Drug Discovery with Professional Experience at Coventry University, United Kingdom. During the professional experience component of the MSc program, she carried out collaborative research study at Renal unit of the University Hospital Coventry and Warwickshire NHS Trust. Where she investigated the incidence of Skin Cancer in Kidney Transplant Recipients Associated with the use of Immunosuppressants. The findings of the study has been presented at several International Conferences including the 5th International Renal Transplantation Conference at Warrick University, United Kingdom on 9th May 2019 and the Virtual Conference titled “The American Transplant Congress (ATC)” which took place in Pennsylvania United States on 30th May to 3rd June 2020.
About Sarah at the following link: https://www.m-medix.com/content/15-pharm-sarah-jonathan-yusuf
Mycophenolate mofetil and the incidence of skin cancer in kidney transplant recipients
Sarah Yusuf1, Himaja Bheemreddy1, Imtiaz Ahmed2, Nithya Krishnan3.
1Faculty of health and life sciences, Coventry University, Coventry, United Kingdom; 2Dermatology, University Hospital Coventry and Warwickshire, Coventry, United Kingdom; 3Renal transplantation and nephrology, University Hospital Coventry and Warwickshire, Coventry, United Kingdom
Over the years there has been a shift in the use of anti-metabolites agents from azathioprine to mycophenolate mofetil (MMF) based immunosuppression, due to its better efficacy and less implication in the development of skin cancer compared to azathioprine. However, MMF is still potentially carcinogenic.
Secondary data of 941 Kidney Transplant Recipients (KTRs) who received kidney transplantation from 1st January1998 to 31st December 2018 were obtained. The incidence of skin cancer was determined in 429 KTRs immunosuppressed with MMF. Chi-square test of independence was used to determine the association between use of MMF based immunosuppression and the development of skin cancer, and to determine the risk factors associated with types of skin cancers developed.
MMF was associated more with the development of Basal cell Carcinoma (BCC) in both males and females 5(41.7%) Vs 5(50%) than Squamous Cell Carcinoma (SCC) 3(25%) Vs 2 (20%). Females had a higher incidence of skin cancer than males (10 (5.8%) Vs 12 (4.7%)) although this was not statistically significant (P=0.582). The BCC subtypes identified in females were nodular superficial and infiltrative BCCs, while males had mainly nodular BCCs. The SCC subtypes in females were moderately differentiated and well differentiated SCCs, while males had mainly moderately differentiated SCC. Being Caucasian and ≥ 50 years of age at transplantation were significantly associated with development of skin cancer (P=0.022 and P=0.005 respectively). Interestingly, Human Leucocyte Incompatible (HLAi) transplants were not associated with development of skin cancer.
We conclude that The BCC and SCC histological subtypes associated with use of MMF were not the aggressive forms. KTRs on MMF based immunosuppression will benefit from regular skin assessments.
There are no comments yet...
